BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37494846)

  • 21. Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
    Fremond S; Andani S; Barkey Wolf J; Dijkstra J; Melsbach S; Jobsen JJ; Brinkhuis M; Roothaan S; Jurgenliemk-Schulz I; Lutgens LCHW; Nout RA; van der Steen-Banasik EM; de Boer SM; Powell ME; Singh N; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Smit VTHBM; Creutzberg CL; Horeweg N; Koelzer VH; Bosse T
    Lancet Digit Health; 2023 Feb; 5(2):e71-e82. PubMed ID: 36496303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
    Radziuviene G; Rasmusson A; Augulis R; Grineviciute RB; Zilenaite D; Laurinaviciene A; Ostapenko V; Laurinavicius A
    Front Oncol; 2021; 11():774088. PubMed ID: 34858854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
    Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
    BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
    de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
    Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.
    Klimov S; Miligy IM; Gertych A; Jiang Y; Toss MS; Rida P; Ellis IO; Green A; Krishnamurti U; Rakha EA; Aneja R
    Breast Cancer Res; 2019 Jul; 21(1):83. PubMed ID: 31358020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Artificial intelligence quantified tumour-stroma ratio is an independent predictor for overall survival in resectable colorectal cancer.
    Zhao K; Li Z; Yao S; Wang Y; Wu X; Xu Z; Wu L; Huang Y; Liang C; Liu Z
    EBioMedicine; 2020 Nov; 61():103054. PubMed ID: 33039706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study.
    Yang Z; Zhang Y; Zhuo L; Sun K; Meng F; Zhou M; Sun J
    Eur J Cancer; 2024 Mar; 199():113532. PubMed ID: 38241820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
    Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
    Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of time to death after distant recurrence in breast cancer patients.
    Sopik V; Sun P; Narod SA
    Breast Cancer Res Treat; 2019 Jan; 173(2):465-474. PubMed ID: 30328050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting breast tumor proliferation from whole-slide images: The TUPAC16 challenge.
    Veta M; Heng YJ; Stathonikos N; Bejnordi BE; Beca F; Wollmann T; Rohr K; Shah MA; Wang D; Rousson M; Hedlund M; Tellez D; Ciompi F; Zerhouni E; Lanyi D; Viana M; Kovalev V; Liauchuk V; Phoulady HA; Qaiser T; Graham S; Rajpoot N; Sjöblom E; Molin J; Paeng K; Hwang S; Park S; Jia Z; Chang EI; Xu Y; Beck AH; van Diest PJ; Pluim JPW
    Med Image Anal; 2019 May; 54():111-121. PubMed ID: 30861443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of anthropometric measures extracted from whole-body CT using deep learning in patients with non-small-cell lung cancer.
    Blanc-Durand P; Campedel L; Mule S; Jegou S; Luciani A; Pigneur F; Itti E
    Eur Radiol; 2020 Jun; 30(6):3528-3537. PubMed ID: 32055950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of α- and β2-adrenoceptor gene expression in breast cancer patients.
    Rivero EM; Martinez LM; Bruque CD; Gargiulo L; Bruzzone A; Lüthy IA
    Br J Clin Pharmacol; 2019 Sep; 85(9):2143-2154. PubMed ID: 31218733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer.
    Gyanchandani R; Lin Y; Lin HM; Cooper K; Normolle DP; Brufsky A; Fastuca M; Crosson W; Oesterreich S; Davidson NE; Bhargava R; Dabbs DJ; Lee AV
    Clin Cancer Res; 2016 Nov; 22(21):5362-5369. PubMed ID: 27185370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
    Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.